Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Boehringer Ingelheim’s Animal Health USA division will reimburse $379,089 in back pay and interest to 75 female employees to resolve alleged wage discrimination at its St. Joseph, Missouri, facility.
The trial remains on clinical hold and continues to indefinitely delay the company’s plans to seek regulatory approval for the treatment.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 21, 2020.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The drug company plans to combine its Cambridge operations at the laboratory and office building at the site by the end of the first half of 2023.
The U.S. FDA placed a hold on the Emergency Use Authorization for convalescent plasma as a potential treatment for COVID-19 over what was described as a lack of robust data supporting its use.
Point-of-care testing is a critical tool in the battle against COVID-19, and researchers in Indiana are working around the clock to deliver rapid tests with high specificity.
In its filing, Sorrento did not provide a reason for Shao’s termination.
Regeneron will distribute REGN-COV-2 in the U.S. and Roche will handle distribution outside the U.S.
Eli Lilly will aim a checkpoint inhibitor it co-developed for the Chinese market at the United States and other western markets.